Shareholders’ (Deficiency) Equity (Tables)

12 Months Ended

Dec. 31, 2023

Stockholders' Equity Note [Abstract]

Schedule of the Status of Options and Changes

A summary of the status of options under the Company’s share option plans as of December 31, 2023 and changes during the relevant period ended on that date is presented below:

	For the year ended December 31, 2023
	Number of options			Weighted average exercise price		Aggregate intrinsic value		Weighted average remaining contractual life (years)
Outstanding at beginning of year		8,237,794		$	5.77	$	2,588		7.24
Granted		3,520,111		$	3.47
Exercised		(43,560	)	$	1.10
Forfeited and cancelled		(1,193,571	)	$	5.68
Outstanding at end of period		10,520,774		$	5.03	$	2,264		7.08
Exercisable options		6,460,049		$	4.60	$	2,264		6.02

Schedule of Summary of the Status of RSUs Under the Plan

A summary of the status of RSUs under the Plan as of December 31, 2023 and changes during the relevant period ended on that date is presented below:

	Number of RSU
Outstanding at beginning of year		924,867
Granted		458,911
Vested		(453,831	)
Forfeited and cancelled		(116,679	)
Outstanding at end of year		813,268

Schedule of total equity-based compensation expense

The total equity-based compensation expense related to all of the Company’s equity-based awards recognized for the years ended December 31, 2021, 2022 and 2023, was comprised as follows:

	Year ended December 31,
	2021		2022		2023
Research and development	$	654	$	4,289	$	5,073
Marketing expenses		7		210		2,379
General and administrative		151		2,249		474
Total share-based compensation expense	$	812	$	6,748	$	7,926